Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIC/LEN FDC vs SBR in Virologically Suppressed People With HIV
NCT07908446Phase 4Not yet recruiting
- Sponsor
- Gilead Sciences
- Start
- Nov 2026
- Primary completion
- Jul 2028
01
Overview
A Phase 4 trial of bictegravir + lenacapavir in human immunodeficiency virus infection (HIV), sponsored by Gilead Sciences. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
bictegravir + lenacapavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07908446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07908446.